Modality
Cell Therapy
MOA
CDK2i
Target
VEGF
Pathway
Checkpoint
DravetMigraine
Development Pipeline
Preclinical
Dec 2017
→ Aug 2026
PreclinicalCurrent
NCT04179595
867 pts·Dravet
2023-10→2026-08·Active
NCT08294250
2,517 pts·Dravet
2017-12→TBD·Terminated
3,384 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-08-175mo awayInterim· Dravet
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
Preclinical
Termina…
Preclinical
Active
Catalysts
Interim
2026-08-17 · 5mo away
Dravet
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04179595 | Preclinical | Dravet | Active | 867 | VA |
| NCT08294250 | Preclinical | Dravet | Terminated | 2517 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D |